A clinical study to assess the safety and effectiveness of tbo-filgrastim in infants,children and adolescents with solid tumors without bone marrow involvement

Registry ID
EUCTR2014-001772-55
Source registry
EUCTR
Status
Completed
Phase
PHASE2
Sponsor
TEVA Pharmaceutical Industries Ltd
Start date
2015-01-26
Completion date
2017-04-03
Last update
2026-08-16

Conditions

Summary

The primary objective of this study is to assess the safety and tolerability of 5 μg/kg tbo-filgrastim in the pediatric population with solid tumors without bone marrow involvement.

Locations

View on source registry